Tvardi Therapeutics Inc
tvarditherapeutics.comTvardi Therapeutics Inc (NASDAQ: TVRD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting the STAT3 signaling pathway. The company has no product revenue and funds operations through capital markets activity, reporting a net loss of $18.2 million for the year ended December 31, 2025, compared to a net loss of $29.4 million for the year ended December 31, 2024. Its lead asset, TTI-101, is in clinical development across three indications: hepatocellular carcinoma (HCC), idiopathic pulmonary fibrosis (IPF), and metastatic breast cancer (mBC). Direct R&D spending on TTI-101 for HCC totaled $3.2 million in FY2025, down from $8.6 million in FY2024. IPF spending was $4.7 million in FY2025 versus $6.7 million in FY2024. A second program, TTI-109, is also in development. Total operating expenses were $26.7 million in FY2025, composed of $18.0 million in R&D and $8.7 million in general and administrative costs. As of December 31, 2025, Tvardi holds trademark registrations for the "TVARDI" mark across multiple jurisdictions including the United States, European Union, China, Japan, Australia, Korea, and the United Kingdom.
Products & Services
TTI-101 is the lead product candidate, a small-molecule STAT3 inhibitor in clinical trials for HCC, IPF, and mBC as of the 10-K filed March 31, 2026. TTI-109 is a second product candidate in development. Neither product is approved or commercialized.
Revenue Model
Tvardi Therapeutics generates no product revenue. The company is pre-commercial and finances operations through equity and capital markets transactions. All spending is directed toward clinical-stage drug development.
Customers & Markets
Tvardi has no commercial customers. Target end markets are oncology (hepatocellular carcinoma, metastatic breast cancer) and fibrotic disease (idiopathic pulmonary fibrosis). Patients in these indications would be the ultimate beneficiaries upon any future approval.
Geographic Exposure
Tvardi holds trademark registrations in the United States, European Union, China, Japan, Australia, Korea, and the United Kingdom as of December 31, 2025. Clinical and operational geographic footprint is not further detailed in the filing excerpts.
Financial Snapshot
Loading...
